Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
- PMID: 20409751
- DOI: 10.1016/S1470-2045(10)70070-X
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Abstract
Background: Historical data and recent studies show that standardised extended (D2) lymphadenectomy leads to better results than standardised limited (D1) lymphadenectomy. Based on these findings, the Dutch D1D2 trial, a nationwide prospectively randomised clinical trial, was undertaken to compare D2 with D1 lymphadenectomy in patients with resectable primary adenocarcinoma of the stomach. The aim of the study was to assess the effect of D2 compared with D1 surgery on disease recurrence and survival in patients treated with curative intent.
Methods: Between August, 1989, and July, 1993, patients were entered and randomised at 80 participating hospitals by means of a telephone call to the central data centre of the trial. The sequence of randomisation was in blocks of six with stratification for the participating centre. Eligibility criteria were a histologically proven adenocarcinoma of the stomach without evidence of distance metastasis, age younger than 85 years, and adequate physical condition for D1 or D2 lymphadenectomy. Patients were excluded if they had previous or coexisting cancer or had undergone gastrectomy for benign tumours. Strict quality control measures for pathological assessment were implemented and monitored. Analyses were by intention to treat. This study is registered with the NCI trial register, as DUT-KWF-CKVO-8905, EU-90003.
Findings: A total of 1078 patients were entered in the study, of whom 996 were eligible. 711 patients underwent the randomly assigned treatment with curative intent (380 in the D1 group and 331 in the D2 group) and 285 had palliative treatment. Data were collected prospectively and all patients were followed up for a median time of 15.2 years (range 6.9-17.9 years). Analyses were done for the 711 patients treated with curative intent and were according to the allocated treatment group. Of the 711 patients, 174 (25%) were alive, all but one without recurrence. Overall 15-year survival was 21% (82 patients) for the D1 group and 29% (92 patients) for the D2 group (p=0.34). Gastric-cancer-related death rate was significantly higher in the D1 group (48%, 182 patients) compared with the D2 group (37%, 123 patients), whereas death due to other diseases was similar in both groups. Local recurrence was 22% (82 patients) in the D1 group versus 12% (40 patients) in D2, and regional recurrence was 19% (73 patients) in D1 versus 13% (43 patients) in D2. Patients who had the D2 procedure had a significantly higher operative mortality rate than those who had D1 (n=32 [10%] vs n=15 [4%]; 95% CI for the difference 2-9; p=0.004), higher complication rate (n=142 [43%] vs n=94 [25%]; 11-25; p<0.0001), and higher reoperation rate (n=59 [18%] vs n=30 [8%]; 5-15; p=0.00016).
Interpretation: After a median follow-up of 15 years, D2 lymphadenectomy is associated with lower locoregional recurrence and gastric-cancer-related death rates than D1 surgery. The D2 procedure was also associated with significantly higher postoperative mortality, morbidity, and reoperation rates. Because a safer, spleen-preserving D2 resection technique is currently available in high-volume centres, D2 lymphadenectomy is the recommended surgical approach for patients with resectable (curable) gastric cancer.
Funding: Dutch Health Insurance Funds Council and The Netherlands Cancer Foundation.
2010 Elsevier Ltd. All rights reserved.
Comment in
-
Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait?Lancet Oncol. 2010 May;11(5):404-5. doi: 10.1016/S1470-2045(10)70098-X. Epub 2010 Apr 19. Lancet Oncol. 2010. PMID: 20409753 No abstract available.
Similar articles
-
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.Br J Cancer. 1999 Mar;79(9-10):1522-30. doi: 10.1038/sj.bjc.6690243. Br J Cancer. 1999. PMID: 10188901 Free PMC article. Clinical Trial.
-
[Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?].Suppl Tumori. 2005 May-Jun;4(3):S84-5. Suppl Tumori. 2005. PMID: 16437920 Italian.
-
The effect of extended lymphadenectomy on survival in patients with gastric adenocarcinoma.J Am Coll Surg. 1995 Jul;181(1):56-64. J Am Coll Surg. 1995. PMID: 7599772
-
Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma.Ann Surg. 2011 May;253(5):900-11. doi: 10.1097/SLA.0b013e318212bff6. Ann Surg. 2011. PMID: 21394009 Review.
-
Extended lymphadenectomy in gastric cancer: when, for whom and why.Ann R Coll Surg Engl. 1998 Jan;80(1):16-24. Ann R Coll Surg Engl. 1998. PMID: 9579122 Free PMC article. Review.
Cited by
-
Analysis of Patient Outcomes following Curative R0 Multiorgan Resections for Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis.J Clin Med. 2024 May 20;13(10):3010. doi: 10.3390/jcm13103010. J Clin Med. 2024. PMID: 38792552 Free PMC article. Review.
-
Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer.Gastric Cancer. 2024 Jul;27(4):760-771. doi: 10.1007/s10120-024-01506-5. Epub 2024 May 14. Gastric Cancer. 2024. PMID: 38744779
-
Gastric Cancer Surgery: Balancing Oncological Efficacy against Postoperative Morbidity and Function Detriment.Cancers (Basel). 2024 Apr 29;16(9):1741. doi: 10.3390/cancers16091741. Cancers (Basel). 2024. PMID: 38730693 Free PMC article. Review.
-
Safety, tolerability, and pharmacokinetics of mitoxantrone hydrochloride injection for tracing in patients with gastric cancer: a single-blind, single-center, phase I clinical trial.Am J Cancer Res. 2024 Apr 15;14(4):1675-1684. doi: 10.62347/LSDV5580. eCollection 2024. Am J Cancer Res. 2024. PMID: 38726280 Free PMC article.
-
How to identify early complications in patients undergoing distal gastrectomy?World J Gastrointest Surg. 2024 Apr 27;16(4):974-981. doi: 10.4240/wjgs.v16.i4.974. World J Gastrointest Surg. 2024. PMID: 38690038 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous